Ferring Pharmaceuticals has appointed professor Klaus Dugi as its executive vice president and chief medical officer; roles that will see him take the helm of its global medical affairs, quality assurance and pharmacovigilance business.
Prior to his new role, Professor Dugi has held various leadership roles at Boehringer Ingelheim, including vice president, global affairs, chief medical officer, and most recently managing director UK and Ireland.
Michel Pettigrew, president of the executive board and chief operating officer, Ferring Pharmaceuticals, said: “Making the industry more patient-centric has always been a top priory for Professor Dugi, and this is perfectly aligned with our company philosophy and commitment so solving unmet patient needs, particularly in the area of reproductive and maternal health.”
Additionally, Professor Dugi will also be a member of the Swiss group’s medical board, effective immediately.